COVID-19 Clinical Trials and Where to Get Treated: May 18, 2020 Update


Here is a quick update on the ever-evolving world of COVID-19 trials.  Since our initial posting on this topic, three weeks ago, the number of trials has grown from 100 to over 300. The number of clinical facilities with clinical trials for COVID-19 has grown from 160 to over 600. The fairly optimistic results about Gilead’s remdesivir, at the beginning of May, was a small sign of hope for patients and their families.  You can seek entrance to these ongoing trials in over 140 facilities in the US and 70 in the EU (list of over 200 clinical facilities in the [...]

COVID-19 Clinical Trials and Where to Get Treated: May 18, 2020 Update2020-05-18T16:50:07+00:00

COVID-19 Clinical Trials and Where to Get Treated


We all know the basics for fighting the COVID-19 virus, like washing our hands and staying socially distant from one another, but what about future vaccines and treatments? There is a lot of talk right now about different companies making progress and potential treatments on their way, but what is available right now? Where can patients go today to get the treatment they need? Below we describe the current treatments that are in the clinic right now and have listed for you all the facilities in the US and EU where patients can find a treatment in development for COVID-19. We [...]

COVID-19 Clinical Trials and Where to Get Treated2020-04-21T20:58:48+00:00

China Reshaping the Clinical Trial Pipeline


Finally, the data is in here at OZMOSI, and we can start tracking and reporting on the clinical development expected to come out of China.  Gone are the days of developing drugs only in the US and then watching them slowly make their way to the rest of the world. China’s current trial pipeline below illustrates a disease area focus that is on par with what we see and expect from the US, EU, and Japan.   And that’s only the beginning.  China is now taking a very active role in developing novel therapies directly, and not just for their own [...]

China Reshaping the Clinical Trial Pipeline2019-07-01T19:42:40+00:00

The Clinical Trial Powershift


Pharmaceutical companies are being pushed aside when it comes to who is driving clinical outcomes. Despite the growing number of industry trials year over year, the pharmaceutical industry is taking a back seat to the even faster growing hospital groups and universities in the same space.  Looking back to the year 2000, 8 out of the top 10 clinical trial sponsors were large pharmaceutical companies.  Historically, over the same time period, pharma companies accounted for more than 30% of all clinical trials. Today, not a single pharmaceutical company rises to the level of top 10 clinical trial sponsors, and they account [...]

The Clinical Trial Powershift2018-10-05T13:47:50+00:00



One of the most common and powerful approaches in NLP provides the content experts an opportunity to label each data segment for a portion of the dataset and then analyze these labels to apply to the rest of the dataset. Some key questions need to be answered when applying this approach in different environments.   For example, how many “expert” labels do we need to create before the classification works effectively?  How can we evaluate this in advance?  Are we limiting ourselves to only extracting from the data what we already believe to be true?  We will discuss that last one in [...]

Go to Top